Actuarial TRM for patients randomized to receive 2 mg/kg of 6MPred. Day-5 responders (A) are patients who continued with tapering doses of 6MPred on day 5 of therapy (n = 19; TRM = 16%). Day-5 nonresponders are patients who had the dose of 6MPred increased on day 5 because of nonresponse or progression of aGvHD (n = 25; TRM = 46%). The difference in TRM between day-5 responders and day-5 nonresponders is significant (P = .007).